Stockscreener 앱 받기
397.27
0.16%
0.63
시간 외 거래:
394.85
-2.42
-0.61%
전일 마감가:
$396.64
열려 있는:
$395.72
하루 거래량:
5.78M
Relative Volume:
4.43
시가총액:
$102.31B
수익:
$10.63B
순이익/손실:
$-479.80M
주가수익비율:
29.80
EPS:
13.33
순현금흐름:
$-1.35B
1주 성능:
-14.33%
1개월 성능:
-11.96%
6개월 성능:
-15.72%
1년 성능:
-0.74%
1일 변동 폭
$386.49
$401.31
1주일 범위
$377.85
$474.19
52주 변동 폭
$377.85
$519.88
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein - Yahoo Finance
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock - MSN
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK™ - GuruFocus.com
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - Reuters.com
Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ra - GuruFocus.com
Vertex Pharmaceuticals announces FDA approval for ALYFTREK By Investing.com - Investing.com UK
Vertex Pharma (VRTX) Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - StreetInsider.com
Vertex Secures FDA Approval for Groundbreaking Once-Daily Cystic Fibrosis Treatment ALYFTREK - StockTitan
Vertex's TRIKAFTA Wins Major FDA Expansion for Cystic Fibrosis Treatment in Young Children - StockTitan
Barclays Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
BMO Capital Markets Lowers Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $520.00 - MarketBeat
HC Wainwright Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? - Yahoo! Voices
Is Vertex Stock A Sell After Non-Opioid Pain Drug Whiffs It? - Investor's Business Daily
Principal Financial Group Inc. Buys 21,649 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results - GuruFocus.com
Vertex Plummets With Pain Drug No Better Than Placebo in Study - MSN
Cystic Fibrosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharma - Barchart
Vertex’s Suzetrigine Disappoints In Phase II Pain Study, But Phase III Planning Under Way - Citeline News & Insights
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug - Yahoo! Voices
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’ - Insider Monkey
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to "Market Perform" Rating by Oppenheimer - MarketBeat
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot - MSN
Oppenheimer downgrades Vertex after lumbosacral radiculopathy study - TipRanks
Bank of America Issues Pessimistic Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Yahoo Finance
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo - Yahoo Finance
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint - BioPharma Dive
Vertex's non-opioid pain drug no better than placebo in sciatica study - FirstWord Pharma
Accenture, Robinhood and Coinbase, Vertex: Market Minute - Yahoo Finance
Vertex Pharmaceuticals is Now Oversold (VRTX) - Nasdaq
Vertex stock plummets as study results show non-opioid pain drug no better than placebo - The Boston Globe
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years - Schaeffers Research
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Invest - GuruFocus.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week LowWhat's Next? - MarketBeat
Vertex Pharmaceuticals Inc. (VRTX) Investigated For - GlobeNewswire
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton ... - The Bakersfield Californian
Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise. - Barron's
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results - MSN
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic - Yahoo Finance
Vertex's painkiller results match placebo in study, shares tumble - Reuters.com
Vertex Phase II suzetrigine study disappoints - The Pharma Letter
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy - BioSpace
Vertex stock touches 52-week low at $389.73 amid market shifts - Investing.com UK
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3 - Yahoo Finance
Vertex’s non-opioid painkiller meets trial goal — but investors aren’t sold - The Business Journals
Vertex Pharma’s suzetrigine meets Phase 2 primary endpoint in radiculopathy - TipRanks
Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors - Fierce Biotech
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
2.75%
자본화:
|
볼륨(24시간):